Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on May 6, 2021, at 10.00 a.m. CET. Xbrane will publish the company’s interim report January – March, 2021, on Thursday the 6th of May, 2021, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report for January - March 2021, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link:
https://edge.media-server.com/mmc/p/eq2kbejf

Standard international: +44 (0) 2071 928 338
UK (Local): +44 (0) 844 481 97 52
UK (Tollfree): 800 279 66 19

Sweden (Local): +46 (0) 856 618 467
Sweden (TollFree): 020 012 51 60

US (Local): +1 646 741 31 67
US (TollFree): +1 877 870 91 35

Confirmation Code: 516 34 48

Contacts

Martin Åmark, CEO
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 (0) 763 256 090
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane is in phase III and filing of marketing authorization application is planned for the latter part of 2021. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Attachments

Invitation to presentation of Xbrane Biopharma’s interim report January – March, 2021 on May 6, 2021.

© Modular Finance, source Nordic Press Releases